Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
Date:7/20/2009

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at patrick.cairns@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com

    Contact:
    Patrick Cairns
    Corporate Communications
    P: +27 18 468 2315
    M: +27 83 258 4219
    E: patrick.cairns@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):